-+ 0.00%
-+ 0.00%
-+ 0.00%

Nyxoah implants first patient in BREATHE US post-approval study of Genio sleep apnea device

PUBT·09/07/2026 20:05:25
Listen to the news
Nyxoah implants first patient in BREATHE US post-approval study of Genio sleep apnea device
  • Nyxoah implanted the first patient in BREATHE, a US post-approval study of its Genio sleep apnea neurostimulation system.
  • No results have been presented; 12-month effectiveness and safety outcomes are scheduled to be assessed, with follow-up extending to five years.
  • The study aims to confirm Genio’s long-term performance in routine US clinical practice, supporting broader adoption and reimbursement discussions.
  • BREATHE plans up to 229 implants across as many as 25 US centers, positioning it as the company’s largest prospective Genio study.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nyxoah SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609071605OMX_____CNEWS_EN_GNW1001261261_en) on September 07, 2026, and is solely responsible for the information contained therein.